DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400
Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad – 380 055
E-mail: dharachem99@yahoo.in

Date: 4th November, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir / Madam,

Sub: Outcome of Board Meeting held today i.e. 4th November, 2026

Ref: Security Id: DPL / Code: 543594

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held today i.e., 4th November, 2026, at the Registered Office of the Company situated at A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055 which commenced at 05:00 P.M. and concluded at 05:30 P.M. has considered and approved the Standalone Unaudited Financial Results for the Quarter ended on 30th June, 2026 along with Limited Review Report.

Kindly take the same on your record and oblige us.

Thanking You

For, Dipna Pharmachem Limited

DIPNA PHARMACHEM LIMITED

Keyur Dipakkumar Shah
Managing Director
DIN: 03167258

KEYUR DIPAKKUMAR SHAH

Digitally signed by KEYUR DIPAKKUMAR SHAH
DN: c=IN, postalCode=380015, st=GUJARAT, street=29, DEVPRIYA BUNGLOWS-2 ,OPP VISHAL RESIDENCY TOWER ,AHMEDABAD,SATELLITE ,380015, l=AHMEDABAD, o=Personal, serialNumber=f30f7a81e11bf421800b1ed52de15af0f1bed4162e9413522d1e8c310773425f, pseudonym=c39eb07fb5724f0f8f99a44f8770314d, 2.5.4.20=188741ccfd7bb11817030510 5c905184ea281d940cca68d5560b850333a10fef, email=INFO@DIPNAPHARMACHEM.COM, cn=KEYUR DIPAKKUMAR SHAH
Date: 2026.11.04 17:33:24 +05'30'

DIPNA PHARMACHEM LIMITED

CIN : L24100GJ2011PLC066400

Reg. Address: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055

Email Id :- dharachem99@yahoo.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE MONTHS ENDED ON 30TH JUNE, 2026

(Amount Rs. in Lakhs)

Sr. No	Particulars	Quarter ended			Year to date		Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	June 30, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Income**						
	Revenue from operations						
	a. Sale of Products and Services	2,033.03	202.49	1850.04	2,033.03	1,850.04	12,908.33
	b. Other operating income	346.03	2.54	-	346.03	-	2.54
	Other Income						
	Total Income	**2,379.06**	**205.03**	**1,850.04**	**2,379.06**	**1,850.04**	**12,910.87**
2	**Expenses**						
	a. Purchase of stock-in-trade	1,890.28	1,354.20	1,872.02	1,890.28	1,872.02	12,237.20
	b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	7.63	(1,542.76)	(421.21)	7.63	(421.21)	(1,489.05)
	c. Employee benefits expense	8.80	10.37	7.97	8.80	7.97	41.12
	d. Finance costs	30.54	23.14	16.06	30.54	16.06	146.32
	e. Depreciation and amortization expense	0.41	0.44		0.41	-	1.43
	f. Other expenses	387.37	336.98	318.02	387.37	318.02	1,614.90
	g. Power and Fuel	1.61	0.38	0.16	1.61	0.16	4.47
	Total Expenses	**2,326.64**	**182.75**	**1,793.02**	**2,326.64**	**1,793.02**	**12,556.39**
3	**Profit before Exceptional items and tax (1-2)**	**52.42**	**22.28**	**57.02**	**52.42**	57.02	**354.48**
4	Exceptional items	-	-	-	-	-	-
5	**Profit before tax (3-4)**	**52.42**	**22.28**	**57.02**	**52.42**	**57.02**	**354.48**
6	Tax expense						
	a. Current Tax	13.00	4.77	-	13.00	-	91.66
	b. Deferred Tax	-	(0.35)	-	-	-	(0.37)
	Total Tax Expense	**13.00**	**4.42**	**-**	**13.00**	**-**	**91.29**
7	**Net profit/(Loss) for the period (5-6)**	**39.42**	**17.86**	**57.02**	**39.42**	57.02	**263.19**
8	**Other Comprehensive income**					-	
	Item that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
9	**Total Comprehensive income (after taxes) (7+8)**	**39.42**	**17.86**	**57.02**	**39.42**	**57.02**	**263.19**
10	Paid up equity share capital (Face value of Rs.10/- each)	2,628.92	2,628.92	2,404.53	2,628.92	2,404.53	2,628.92
11	Other equity (Reserves)	1,813.80	1,774.39	1,501.77	1,813.80	1,501.77	1,774.39
12	**Earning per equity share**						
	a.Basic	0.15	0.07	0.24	0.15	0.24	1.00
	b.Diluted	0.15	0.07	0.24	0.15	0.24	1.00

Notes:

1. Number of Investors complaints received, disposed of and lying unresolved as on 30.06.2026: NIL
2. The above results have been reveiwed by audit committee and approved by the Board of Directors at their meeting held on 4th November, 2026
3. Previous year figures have been regrouped / reclassified wherever necessary to confirm to the current financial year figures and as per Schedule III
4. The Company does not have any subsidiary company.
5. Beginning April 1, 2025, the Company has, for the first time adopted IND AS with transition date of April 1, 2024 and accordingly the above audited Financial Results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under.
6. As the Company is having only one segment i.e. Chemicals Segment, there are no reportable segment in accordance with the requirement of Accounting Standard (As-17) "Segment Reporting" specified under Section 133 of the Companies Act, 2013.
7. There was no adjustment in the profit & loss for Q1 (F.Y. 2026-27) under IND AS.

DIPNA PHARMACHEM LIMITED

For, Dipna Pharmachem Limited

Keyur Shah
Managing Director
DIN: 03167258

Place : Ahmedabad
Date : 4th November, 2026

DEVADIYA & ASSOCIATES
CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors of
Dipna Pharmachem Limited

We have reviewed the accompanying statement of unaudited financial results of DIPNA **PHARMACHEM LIMITED** (PAN: **AADCD9404F)** for the period ended 30th June, 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Devadiya & Associates
Chartered Accountants
FR NO: 123045W

DEVADIYA & ASSOCIATES ☆ AHMEDABAD F.R.N. 123045W M.NO. 112495 ☆ CHARTERED ACCOUNTANTS

CA Sanjay Devadiya
M No: 112495
UDIN: 26112495MZQBKY8564
Place: Ahmedabad
Date: 04/11/2026

A-301, The First, B/h ITC Narmada Hotel, Vastrapur,
Ahmedabad 380015. Voice:- 079-40326703, 079-4007618
Email:- info@devadiya.com Web.:- www.devadiya.com.
Offices at:- Ahmedabad, Baroda & Banswara